Cabozantinib with nivolumab and ipilimumab for previously untreated advanced or metastatic renal cell carcinoma

Cabozantinib in combination with nivolumab and ipilimumab is in clinical development for the treatment of adults with previously untreated advanced or metastatic renal cell carcinoma (RCC) with intermediate or poor risk. Advanced cancer is when the cancer is late stage and can’t be surgically removed, whereas metastatic is when the cancer has also spread to other areas of the body. RCC is also known as kidney cancer and is one of the 7th most common cancers in the UK. RCC usually affects adults in their 60s and 70s, and people aged 85 to 89 have the highest rate of kidney cancer. In early stages it can be asymptomatic (no symptoms), but symptoms include blood in urine, lower back or side pain, high blood pressure, loss of appetite and weight, bone pain, breathing difficulties, tiredness, high temperature, night sweats, swollen neck glands and coughing up blood. There is a need for additional treatment options to improve patient outcomes.